Recurrent loss of heterozygosity correlates with clinical outcome in pancreatic neuroendocrine cancer
B. Lawrence, C. Blenkiron, K. Parker, P. Tsai, S. Fitzgerald, P. Shields, M. L. Yeong, N. Kramer, T. Robb, S. M. James, M. Black, V. Fan, N. Poonawala, P. Yap, E. Coats, , C. G. Print
The paper identifies two distinct aneuploidy patterns in pancreatic neuroendocrine tumors (pNETs) associated with poor and good clinical outcomes, respectively, and highlights MEN1 mutations as a significant driver.
bioRxiv · Nov 8, 2017Cancer Biology